Abstract Library

#4128 Validation of a 3-gene signature of response to axitinib in patients with advanced NETs

Introduction: Axitinib in combination with SSA significantly improved ORR and PFS per central blinded radiological assessment, as compared to placebo and SSA in 253 EP-NETs in the AXINET trial. The magnitude of the benefit, however, was limited. We recently described a 3-gene tumor transcriptomic signature predictive of response to axitinib in NET patients.

Conference:

Presenting Author: Lens-Pardo A

Authors: Lens-Pardo A, Carretero-Puche C, Antón-Pascual B, Capdevila J, Benavent M,

Keywords: axitinib, sunitinib, tyrosine kinase inhibitor, predictive biomarker, signature, elisa,

#4086 Prognostic significance of metabolomics clusters in extra-pancreatic NETs: Lung NET sub-analysis

Introduction: Metabolic flexibility is one of the key hallmarks of cancer and metabolites are the final products of this adaptation, reflecting the aberrant changes that support cancer cells proliferation and survival. In a previous metabolomics study carried out by our group, multiplatform untargeted metabolomic profiling (GC-MS, CE-MS and LC-MS) performed on plasma samples from 77 advanced G1-2 extra-pancreatic NET patients demonstrated that these patients have a distinct metabolomic profile, and identified methionine, porphyrin and tryptophan metabolism as the most relevant dysregulated pathways associated with the prognosis of NETs. Furthermore, a 3-metabolite signature was able to stratify patients in 3 distinct prognostic clusters, with cluster 3 associated with the best prognosis.

Conference:

Presenting Author:

Authors: La Salvia A, Lens-Pardo A, Carretero-Puche C, Capdevila J, Benavent M,

Keywords: metabolimics, prognostic biomarker, lung neuroendocrine tumor, metabolomic signature,

#4015 Responses to Cabozantinib plus Atezolizumab in a wide population of advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II Trial (CABATEN / GETNE-T1914)

Introduction: Angiogenesis plays a key role in development and progression of NENs and synergism has been observed when combined with immune-checkpoint inhibitors in other tumors.

Conference:

Presenting Author: Molina-Cerrillo J

Authors: Molina-Cerrillo J, Grande E, Benavent M, Garcia-Carbonero R, Teule A,

Keywords: neuroendocrine neoplasm, Cabozantinib, Atezolizumab, CABATEN, prospective multi-cohort Basket Phase II Trial,

#3811 Multi-omic factor analysis (MOFA) of well-differentiated neuroendocrine tumors (NETs) from different tumor sites

Introduction: NENs are a heterogeneous family of tumors of wide anatomical distribution that share common clinical and biological traits. Although some studies have characterized the molecular landscape of specific primary locations, there is no cross-site molecular classification of NENs.

Conference:

Presenting Author: Carretero C

Authors: Carretero C, Antón-Pascual B, Lens-Pardo A, Benavent M, Gómez-Izquierdo L,

Keywords: NET, MOFA, multi-omics, clinical features, survival,

#3768 Predictive transcriptomic signature of response to axitinib in patients with advanced NETs included in the randomized, double-blind, placebo-controlled AXINET trial (GETNE 1107)

Introduction: Axitinib in combination with Octreotide LAR significantly improved ORR (13.2 vs 3.2%, OR 4.58, p=0.0045) and PFS (16.6 vs 9.9m, HR 0.71, p=0.017) per central blinded radiological assessment, as compared to placebo and SSA, in 256 patients with EP-NETs included in the AXINET trial (Garcia-Carbonero et al, ESMO 2021). The magnitude of the benefit, however, was limited.

Conference:

Presenting Author: Lens-Pardo A

Authors: Lens-Pardo A, Carretero C, Antón-Pascual B, Capdevila J, Benavent M,

Keywords: Axitinib, Tyrosine kinase inhibitor, predictive biomarker, signature,